Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
Overview
- Phase
- Phase 2
- Intervention
- OC-02 (simpinicline) nasal spray
- Conditions
- Dry Eye Disease
- Sponsor
- Oyster Point Pharma, Inc.
- Enrollment
- 53
- Locations
- 2
- Primary Endpoint
- Mean Change in Schirmer's Test From Baseline to 28 Days
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The objective of this study is to evaluate the safety and effectiveness of OC-02 nasal spray compared to placebo on signs and symptoms of dry eye disease (DED).
Detailed Description
This was a Phase 2, multicenter, randomized, double-masked, placebo-controlled study designed to evaluate the safety and efficacy of OC-02 Nasal Spray in adult subjects with dry eye disease. Approximately 45 subjects, at least 22 years of age, with a history of dry eye disease and meeting all other study eligibility criteria were planned to be randomized to receive an application of OC-02 or placebo twice daily (BID) for 4 weeks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 60 days prior to Visit 1
Exclusion Criteria
- •Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such as blepharoplasty) in either eye within three months or refractive surgery (e.g. laser epithelial keratomileusis, laser-assisted in-situ keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1
- •Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with dry eye disease are allowed.
- •Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
- •Have a known hypersensitivity to any of the procedural agents or study drug components
- •Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject
Arms & Interventions
OC-02 (simpinicline) spray spray, 11.1 mg/ml
OC-02 (simpinicline) nasal spray, 11.1 mg/ml
Intervention: OC-02 (simpinicline) nasal spray
Placebo
Placebo (vehicle) nasal spray
Intervention: Placebo (vehicle) nasal spray
Outcomes
Primary Outcomes
Mean Change in Schirmer's Test From Baseline to 28 Days
Time Frame: 28 days [Visit 1 (baseline) and Visit 5 (28 Days)]
The primary end point was the change in anesthetized Schirmer's Test Score (STS) from baseline to 28 days in the study eye following treatment with OC-02. Schirmer's test score from 0-35 mm where a higher score is indicative of a better outcome.